Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00568594
Recruitment Status : Completed
First Posted : December 6, 2007
Last Update Posted : October 29, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacokinetics and pharmacodynamics of single and multiple daily intravenous infusions of APL018 in patients with CHD

Condition or disease Intervention/treatment Phase
Coronary Heart Disease Drug: APL180 Drug: Placebo Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 176 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A First-in-human, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose (Healthy Volunteers and CHD Patients) and Multiple Dose (CHD Patients) Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
Study Start Date : November 2007
Actual Primary Completion Date : September 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: APL180
Placebo Comparator: 2 Drug: Placebo

Primary Outcome Measures :
  1. Safety and tolerability, pharmacokinetics and effects on biomarkers of HDL function of APL180 after a single and 7-daily infusions in healthy volunteers (HV) and in patients with coronary heart disease (CHD) [ Time Frame: throughout the study ]

Secondary Outcome Measures :
  1. Pharmacokinetic/pharmacodynamic relationship after a single and 7 daily infusions in CHD patients [ Time Frame: throughout the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female healthy volunteers (ages 18-55 years) and patients with CHD (ages 18 to 75 years) on stable statin therapy for at least 8 weeks, with normal liver and kidney function.
  • Women who are post-menopausal, surgically sterile, or practicing effective contraception. Additional birth control details to be provided at screening.
  • Body mass index (BMI) must be within the range of 20 to 35 for CHD patients or CHD equivalents.
  • Clinical CHD:
  • Myocardial infarction (MI), angina, revascularization (e.g. CABG, stent) at least 6 months prior to inclusion
  • CHD equivalents:
  • symptomatic carotid artery disease (e.g. transient ischemic attack or stroke of carotid origin) or peripheral artery disease or abdominal aortic aneurysm or Diabetes Mellitus (HbA1c ≤9)
  • 20% 10 year risk of CHD (Framingham point score: ≥16 (men), ≥23 (women))
  • Other clinical forms of atherosclerotic disease including >50 percent stenosis on angiography or ultrasound
  • Male subjects, when sexually active, using one form of highly effective contraception (e.g. condom)

Exclusion Criteria for both healthy volunteers and patients:

  • Smokers (use of tobacco products in the previous 3 months). Smokers who report cigarette use of more then 10 cigarette per day or have a urinary cotinine level greater then 500 ng/ml.
  • Pregnancy.
  • Use of any prescription drugs within four (4) weeks prior dosing, or over-the-counter (OTC) medication (vitamins, herbal supplements, dietary supplements) within two (2) weeks prior to dosing. Significant illness within two weeks prior to dosing.
  • Significant illness within two weeks prior to dosing.
  • A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome.
  • History of clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug or any allergic reaction to prior receipt of protein therapies or vaccines.
  • Presence of NYHA Class III or IV CHF or unstable angina pectoris.
  • MI or within angioplasty (including stenting), acute coronary syndrome (ACS), unstable angina or arterial embolic disease within 6 months prior to dosing.
  • Use of certain medications prohibited by the protocol.
  • Uncontrolled diabetes (HbA1c > 9).
  • Uncontrolled hypertension (Systolic BP >160 mm Hg and/or Diastolic BP >100 mmHg on two consecutive measurements).
  • Liver or kidney disease confirmed by abnormal lab values or function.
  • Serum creatine kinase CK (CPK) total > 2x.
  • CHD equivalent patients with a history of early positive exercise stress test.

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00568594

United States, Pennsylvania
Novartis Investigator Site
Philadelphia, Pennsylvania, United States
Novartis Investigator Site
Antwerp, Belgium
Novartis Investigator Site
Birkeroed, Denmark
Novartis Investigator Site
Jerusalem, Israel
Novartis Investigator Site
Tel-Aviv, Israel
Novartis Investigator Site
Tzrifin, Israel
Novartis Investigator Site
Groningen, Netherlands
South Africa
Novartis Investigator Site
Bloemfontein, South Africa
Novartis Investigator Site
George, South Africa
Novartis Investigator Site
Port Elizabeth, South Africa
United Kingdom
Novartis Investigator Site
Harrow, United Kingdom
Sponsors and Collaborators
Principal Investigator: NOVARTIS Novartis investigative site

Responsible Party: Novartis Identifier: NCT00568594     History of Changes
Other Study ID Numbers: CAPL180A2201
First Posted: December 6, 2007    Key Record Dates
Last Update Posted: October 29, 2012
Last Verified: October 2012

Keywords provided by Novartis:
Apolipoprotein A-I,

Additional relevant MeSH terms:
Heart Diseases
Coronary Disease
Coronary Artery Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases